Holen Sie sich die Stockscreener-App
18.15
5.10%
0.88
Vorhandelsmarkt:
18.31
0.16
+0.88%
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media
A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga
Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo
Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock - MarketBeat
Amneal Pharmaceuticals Insiders Sold Shares Worth Over $6.3M - TradingView
Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings - Stock Titan
AMRX (AMRX) files notice to sell 50,000 common shares - Stock Titan
What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders - Sahm
Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan
Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO gains 6.38M shares in Kashiv acquisition - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal - Stock Titan
AMRX (AMRX) plans Rule 144 resale of 146,403 equity compensation shares - Stock Titan
Amneal Pharmaceuticals, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine? - Yahoo Finance
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? - Yahoo Finance
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Shares Fall 4.3% -- GF Value S - GuruFocus
Charles Schwab Corp (AMRX): holder files Form 144 for 2.92M-share sale - Stock Titan
Amneal closes $1.1B Kashiv Biosciences acquisition - NJBIZ
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Amneal Pharma completes acquisition of Kashiv BioSciences - Pharmabiz.com
California State Teachers Retirement System Purchases 56,588 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals Adds $350 Million Incremental Term Loan to Fund Kashiv Acquisition - TradingView
Amneal completes acquisition of Kashiv BioSciences By Investing.com - Investing.com UK
Amneal acquires Kashiv BioSciences, creating global biosimilars leader - Telangana Today
Amneal completes acquisition of Kashiv BioSciences - Investing.com
Amneal Pharmaceuticals Completes Kashiv BioSciences Acquisition - Moomoo
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader - The Manila Times
Amneal's New Global Platform Spans Biosimilar Research to Commercialization - Stock Titan
Oliver Luxxe Assets LLC Has $1.46 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Renaissance Technologies LLC Acquires 260,237 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality - webull.com
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segall Bryant & Hamill LLC Sells 113,969 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Evaluating a Robust 7.43% Potential Upside - DirectorsTalk Interviews
Amneal Reprices $2.08B Term Loan, Cuts Margin 50 Bps; Sees ~$12M Annual Interest Savings - TradingView
UBS raises Amneal Pharmaceuticals price target on biosimilar growth - Investing.com
UBS Adjusts Price Target on Amneal Pharmaceuticals to $25 From $23, Maintains Buy Rating - marketscreener.com
amneal pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Bank of New York Mellon Corp - MarketBeat
Sei Investments Co. Has $8.78 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Dimensional Fund Advisors LP Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal (AMRX) Stock Looks About Fair Value On Current Earnings - Yahoo Finance
Healthcare of Ontario Pension Plan Trust Fund Increases Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q2 Revenue $796.2M, vs. FactSet Est of $768.2M - marketscreener.com
Amneal: Q2 Earnings Snapshot - KING5.com
Amneal Reports Second Quarter 2026 Financial Results - GlobeNewswire
Amneal Debt Repricing Expected to Save About $12M a Year - Stock Titan
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1 - Yahoo Finance
Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD By Investing.com - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's What Happened - MarketBeat
Amneal Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals, Inc. Class A Revenue Breakdown – FWB:2DT - TradingView
AMRX|Amneal Pharmaceuticals Inc|Price:17.920|Chg%:-0.050 - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Institutional Confidence - TradingKey
How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats - Sahm
ETFs Investing in Amneal Pharmaceuticals, Inc. Class A Stocks - TradingView
Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
0.79%
5.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):